Posts tagged LabStyle
Rodman starts LabStyle Innovations at buy

Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.

LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.

Read More